Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

22 Results

  • Q&A Session: The Current Evidence On Telemedicine-Delivered Treatment for Opioid and Other Substance Use Disorders

    Contains 3 Component(s) Includes a Live Web Event on 10/21/2020 at 6:00 PM (EDT)

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN).

    Q&A Session for the 10/14/2020 webinar.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

    Allison Lin, MD

    Allison Lin, MD is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry as well as a research investigator at the VA Center for Clinical Management Research. She investigates ways to improve treatment for patients with opioid and other substance use disorders and uses large electronic health datasets to better understand medical, mental health and other correlates for patients with substance use disorders. Dr. Lin is interested in developing telehealth interventions to improve access to evidence based treatments for substance use disorders and to better understand disparities in treatment. 

    Areas of Interest

    ·         Improving access to opioid and other substance use disorder treatment

    ·         Improving care for patients with substance and other comorbid mental health disorders

    ·         Reducing drug overdose

    ·         Interventions to promote safer opioid prescribing

    Credentials

    ·         Addiction Psychiatry Research & Clinical Fellow, Department of Psychiatry, University of Michigan Medical School 

    ·         Adult Psychiatry Residency, Department of Psychiatry, University of Michigan Medical School

    ·         M.D. Yale University School of Medicine B.S. in Chemical Engineering and Economics, Massachusetts Institute of Technology

  • The Current Evidence On Telemedicine-Delivered Treatment for Opioid and Other Substance Use Disorders

    Contains 3 Component(s) Includes a Live Web Event on 10/14/2020 at 6:00 PM (EDT)

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN).

    This presentation will describe background on current challenges with substance use disorder (SUD) treatment access and delivery and present evidence for telemedicine for SUD treatment based on a recent systematic review published by the speaker and describe gaps in the research knowledge to date.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

    Allison Lin, MD

    Allison Lin, MD is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry as well as a research investigator at the VA Center for Clinical Management Research. She investigates ways to improve treatment for patients with opioid and other substance use disorders and uses large electronic health datasets to better understand medical, mental health and other correlates for patients with substance use disorders. Dr. Lin is interested in developing telehealth interventions to improve access to evidence based treatments for substance use disorders and to better understand disparities in treatment. 

    Areas of Interest

    ·         Improving access to opioid and other substance use disorder treatment

    ·         Improving care for patients with substance and other comorbid mental health disorders

    ·         Reducing drug overdose

    ·         Interventions to promote safer opioid prescribing

    Credentials

    ·         Addiction Psychiatry Research & Clinical Fellow, Department of Psychiatry, University of Michigan Medical School 

    ·         Adult Psychiatry Residency, Department of Psychiatry, University of Michigan Medical School

    ·         M.D. Yale University School of Medicine B.S. in Chemical Engineering and Economics, Massachusetts Institute of Technology

  • Q&A - Telemedicine for OUD in the Indian Health Service

    Contains 3 Component(s) Includes a Live Web Event on 08/26/2020 at 4:00 PM (EDT)

    This webinar is part of the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This webinar is part of the telehealth series for the Opioid Response Network (ORN).

    Patients who receive care in the IHS system often live in rural areas where economic and transportation challenges can make accessing medications for OUD treatment difficult.  Telemedicine can remove many barriers to OUD treatment for Native American/Alaskan patients.  Dr. Spencer will discuss how telemedicine for OUD is being used in the Alaskan native medical system and elsewhere.  Topics covered will include IHS specific legal concerns,  home induction and remote urine drug testing, remote harm reduction services, remote behavioral health support and use of monthly injectable medications.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

    Sarah Spencer, DO

    Dr. Spencer grew up rural central Maine and did her medical training there during the peak of the Oxycontin epidemic in 2001-2009.  She is board certified in family and addiction medicine has been providing treatment for OUD in rural Alaska since 2010.   For the past 5 years Dr. Spencer has been providing opioid overdose response training and naloxone distribution, and 2016 she became the medical director and founding member of Alaska’s only rural syringe access program.  She is currently an employee of the Ninilchik Traditional Council and provides family medicine and addiction treatment services at their tribal clinic, including telemedicine to remote native villages.  She teaches on addiction issues across the state of Alaska, including buprenorphine waiver certification courses. She participated in the treatment advisory committee for developing the 2019 Alaska state opioid task force recommendations and co-authoring the state’s medication assisted treatment guide and is the state’s senior physician consultant for the SAHMSA funded Opioid Response Network consulting program.  

  • Telemedicine for OUD in the Indian Health Service

    Contains 3 Component(s) Includes a Live Web Event on 08/19/2020 at 4:00 PM (EDT)

    This is the fourth webinar in the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the fourth webinar in the telehealth series for the Opioid Response Network (ORN).

    Patients who receive care in the IHS system often live in rural areas where economic and transportation challenges can make accessing medications for OUD treatment difficult.  Telemedicine can remove many barriers to OUD treatment for Native American/Alaskan patients.  Dr. Spencer will discuss how telemedicine for OUD is being used in the Alaskan native medical system and elsewhere.  Topics covered will include IHS specific legal concerns,  home induction and remote urine drug testing, remote harm reduction services, remote behavioral health support and use of monthly injectable medications.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

    Sarah Spencer, DO

    Dr. Spencer grew up rural central Maine and did her medical training there during the peak of the Oxycontin epidemic in 2001-2009.  She is board certified in family and addiction medicine has been providing treatment for OUD in rural Alaska since 2010.   For the past 5 years Dr. Spencer has been providing opioid overdose response training and naloxone distribution, and 2016 she became the medical director and founding member of Alaska’s only rural syringe access program.  She is currently an employee of the Ninilchik Traditional Council and provides family medicine and addiction treatment services at their tribal clinic, including telemedicine to remote native villages.  She teaches on addiction issues across the state of Alaska, including buprenorphine waiver certification courses. She participated in the treatment advisory committee for developing the 2019 Alaska state opioid task force recommendations and co-authoring the state’s medication assisted treatment guide and is the state’s senior physician consultant for the SAHMSA funded Opioid Response Network consulting program.  

  • Q&A Session - Telehealth for Opioid Use Disorder during the COVID-19 Pandemic and Beyond

    Contains 3 Component(s)

    This is the third webinar in the telehealth series for the Opioid Response Network (ORN). There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders. This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted. Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is part of the third webinar in the telehealth series for the Opioid Response Network (ORN).

    There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders.   

     This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Shabana Khan, MD

    Shabana Khan, MD has a decade of experience in telemedicine. She is an Assistant Professor and the Director of Telepsychiatry for the Department of Child and Adolescent Psychiatry at NYU Langone Health in New York City.

    She is Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Telepsychiatry Committee, Chair of the NYU Grossman School of Medicine Telemedicine Taskforce, and member of the American Psychiatric Association (APA) Telepsychiatry Committee.

    Dr. Khan is an expert in undergraduate and graduate medical education and training in telemedicine.

    Through her active involvement and collaboration with the American Telemedicine Association (ATA), APA, AACAP, and Center for Telehealth and e-Health Law (CTeL), Dr. Khan has helped inform telemedicine legislation, policy, and regulations at the federal and state level.

    Dr. Khan received a B.A. in Neuroscience from Barnard College and an M.D. from SUNY Downstate College of Medicine. She completed general adult psychiatry residency and child and adolescent psychiatry fellowship at Western Psychiatric Hospital of the University of Pittsburgh Medical Center (UPMC). She is board-certified in General Psychiatry and Child and Adolescent Psychiatry.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Telehealth for Opioid Use Disorder during the COVID-19 Pandemic and Beyond

    Contains 3 Component(s)

    This is the third webinar in the telehealth series for the Opioid Response Network (ORN). There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders. This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted. Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is the third webinar in the telehealth series for the Opioid Response Network (ORN).

    There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders.   

     This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Shabana Khan, MD

    Shabana Khan, MD has a decade of experience in telemedicine. She is an Assistant Professor and the Director of Telepsychiatry for the Department of Child and Adolescent Psychiatry at NYU Langone Health in New York City.

    She is Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Telepsychiatry Committee, Chair of the NYU Grossman School of Medicine Telemedicine Taskforce, and member of the American Psychiatric Association (APA) Telepsychiatry Committee.

    Dr. Khan is an expert in undergraduate and graduate medical education and training in telemedicine.

    Through her active involvement and collaboration with the American Telemedicine Association (ATA), APA, AACAP, and Center for Telehealth and e-Health Law (CTeL), Dr. Khan has helped inform telemedicine legislation, policy, and regulations at the federal and state level.

    Dr. Khan received a B.A. in Neuroscience from Barnard College and an M.D. from SUNY Downstate College of Medicine. She completed general adult psychiatry residency and child and adolescent psychiatry fellowship at Western Psychiatric Hospital of the University of Pittsburgh Medical Center (UPMC). She is board-certified in General Psychiatry and Child and Adolescent Psychiatry.

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Essentials: Prescribing Naloxone to Patients for Overdose Reversal

    Contains 4 Component(s), Includes Credits

    This lecture is designed to provide the learner with brief history of the events in the late 1990s that resulted in today's opioid epidemic, discuss the epidemiology of opioid overdose and the neurobiology of overdose. Risk factors for overdose, the use of naloxone for overdose, and state laws regarding prescribing naloxone will be discussed.

    This lecture is designed to provide the learner with brief history of the events in the late 1990s that resulted in today's opioid epidemic, discuss the epidemiology of opioid overdose and the neurobiology of overdose.  Risk factors for overdose, the use of naloxone for overdose, and state laws regarding prescribing naloxone will be discussed.

    Goals and Objectives:

    At the conclusion of this activity participants should be able to: 

    • Discuss how the opioid prescribing epidemic is associated with the overdose epidemic
    • Discuss opioid overdose risk factors
    • Describe the basic pharmacology of naloxone
    • Describe studies demonstrating the efficacy of naloxone in bystander overdose
    • Name the four different forms of naloxone available for bystander reversal of overdose and discuss to prescribe it

    Julie Kmiec, DO (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Essentials: Alcohol Use Problems: Recommendations for Medical Management

    Contains 4 Component(s), Includes Credits

    Alcohol is the most commonly used intoxicant in the world. There are a variety of physical, behavioral, and societal problems that can result from drinking alcohol in a risky or dependent pattern. This presentation will review some of t the development components, the acute treatments, and the long term treatments available. The program will stress the importance of a longitudinal approach to the treatment of the effected patient.

    Alcohol is the most commonly used intoxicant in the world.  There are a variety of physical, behavioral, and societal problems that can result from drinking alcohol in a risky or dependent pattern.  This presentation will review some of t the development components, the acute treatments, and the long term treatments available.  The program will stress  the importance of a longitudinal approach to the treatment of the effected patient. 

    Learning Objectives:

    1. The developmental components of alcohol use problems.
    2. The commonly used medication assisted withdrawal techniques.
    3. The importance of monitoring and encouraging ongoing treatment at the appropriate level of care of these patients.
  • Essentials: 12 Step Program

    Contains 4 Component(s), Includes Credits

    We explain why 4-5 million people use 12 step methods & more people are seeking help for addiction to drugs and alcohol.

    We explain why 4-5 million people use 12 step methods & more people are seeking help for addiction to drugs and alcohol. 

    Objectives:

    1. List the 12 steps’ list the history
    2. Explain the risks and benefits of 12 steps

    R. Gregory Lande, DO, FAOAAM (Moderator)

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Essentials: Psychosocial Treatments for Substance Use Disorder

    Contains 4 Component(s), Includes Credits

    This lecture will review the co-morbid medical and behavioral treatments in the field of addiction medicine. Addiction Medicine patients have a higher rate of medical and psychiatric disorders and this often complicates the treatment of the addiction. Screening and evaluation process for medical and behavioral issues will be reviewed. Screening tools for PTSD, Depression and the Mental Status Examination will be reviewed in detail. Medical screening laboratory and toxicology screens will be discussed. Infectious disease evaluation and care is of critical importance in light of HIV, HEP C and other infectious processes. Treatment of chronic medical disorders including pain syndromes may complicate the treatment of addiction patients.

    This lecture will review the co-morbid medical and behavioral treatments in the field of addiction medicine.  Addiction Medicine patients have a higher rate of medical and psychiatric disorders and this often complicates the treatment of the addiction.  Screening and evaluation process for medical and behavioral issues will be reviewed. Screening tools for PTSD, Depression and the Mental Status Examination will be reviewed in detail.  Medical screening laboratory and toxicology screens will be discussed.  Infectious disease evaluation and care is of critical importance in light of HIV, HEP C and other infectious processes.  Treatment of chronic medical disorders including pain syndromes may complicate the treatment of addiction patients. 

    Objectives:

    • To be aware of the medical co-morbid disorders associated with addictions 
    • Be able to list the topics to be covered in a screening examination 
    • To be aware of the psychosocial interventions for addiction patients including behavioral, Osteopathic interventions and sober support programs. 

    R. Gregory Lande, DO, FAOAAM (Moderator)

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.